IMAGE

0420/08-08-03

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. 0788.00063

In Re Application Of:

Michael A. Tainsky, et al.

Serial No.	Filing Date	Examiner	Group Art Unit
10/004,587	12-04-01	Unknown	Unknown

Title:

NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

   ☐ the statement specified in 37 CFR 1.97(e);

   OR

   ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. 0788.00063

In Re Application:

Michael A. Tainsky, et al.

Serial No.	Filing Date	Examiner	Group Art Unit
10/004,587	**12-04-01**	**Unknown**	**Unknown**

NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **11-1449** as described below. A duplicate copy of this sheet is enclosed.
  - ☐ Charge the amount of
  - ☐ Credit any overpayment.
  - ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

_____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited **8-6-03** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Connie Herty

Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Dated: **August 6, 2003**

Kenneth I. Kohn, Reg. No. 30,955
KOHN & ASSOCIATES, PLLC
30500 Northwestern Highway, Suite 410
Farmington Hills, Michigan 48334
(248) 539-5050

cc:

	√	Gotlieb, W.H. et al., "Presence of Interleukins in the Ascites of Patients with Ovarian and other Intra-Abdominal Cancers," *Cytokine*, 4:385-390 (1992).
	√	Greenlee, R.T. et al., "Cancer Statistics, 2000" *CA Cancer J Clin*, 50:7-33 (2000).
	√	Heath, S. et al., "Induction of Oblique Decision Trees," Machine Learning, 1002-1007 (1993).
	√	Hogdall, E.V. et al., "Predictive Values of Serum Tumour Markers Tetranectin, OVX1, CASA and CA125 in Patients with a Pelvic Mass," *Int J Cancer*, 89:519-523 (2000).
	√	Holschneider, C.H. et al., "Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors," *Semin Surg Oncol*, 1:3-10 (2000).
	√	Houts, T.M., "Improved 2-Color Normalization For Microarray Analyses Employing Cyanine Dyes," *CAMDA* (2000); "Critical Assessment of Techniques for Microarray Data Mining," Duke University Medical Center (2000).
	√	Jacobs I, et al., "The CA 125 Tumor-Associated Antigen: A Review of the Literature," *Hum Reprod*, 4:1-12 (1989).
	√	Jacobs, I. et al., "Multimodal Approach to Screening For Ovarian Cancer," *Lancet*, I 268-271 (1988).
	√	Jacobs, I.J. et al., "Potential Screening Tests for Ovarian Cancer," *London, Chapman and Hall Medical*, 197-205 (1997).
	√	Kacinski BM et al., "Macrophage Colony-Stimulating Factor is Produced by Human Ovarian and Endometrial Adenocarcinoma-Derived Cell Lines and is Present at Abnormally High Levels in the Plasma of Ovarian Carcinoma Patients with Active Disease," *Cancer Cells*, 7:333-337 (1989).
	√	Kerr, Martin, Churchill, "Analysis of Variance for Gene Expression Microarray Data," *Journal of Computational Biology* (2000).
	√	Kim, Si Young et al., "Coordinate Control of Growth and Cytokeratin 13 Expression by Retinoic Acid," *Molecular Carcinogenesis*, 16:6-11 (1996).
	√	Kohonen T., "Learning Vector Quantization," *In the handbook of brain theory and neural networks*, 537-540 (1995).
	--	Kohonen T., "Learning Vector Quantization," *Neural Networks*, 1 (suppl.1):303 (1988).
	√	Lindstrom MS. et al., "p14ARF Homozygous Deletion or MDM2 Overexpression in Burkitt Lymphoma Lines Carrying Wild Type p53," *Oncogene*. 20(17):2171-7 (2001).
	√	MacBeath G. et al., " Printing Proteins as Microarrays for High-Throughput Function Determination," *Science*, 289:1760-3 (2000).
	√	Murthy K., "On Growing Better Decision Trees From Data," Unpublished Doctoral Dissertation. John Hopkins University (1995).
	√	Musavi M. et al., "On the Training of Radial Basis Function Classifiers," *Neural Networks* 5:595-603 (1992).
	√	Nakashima M. et al. "Inhibition of Cell Growth and Induction of Apoptotic Cell Death By the Human Tumor-Associated Antigen RCAS1," *Nat Med*, 5:938-42 (1999).
	√	Patsner B. et al., "Comparison of Serum CA 125 and Lipid Associated Sialic Acid (LASA-P) in Monitoring Patients with Invasive Ovarian Adenocarcinoma," *Gynecol Oncol*, 30(1): 98-103 (1988).
	√	Peng YS. et al., "ARHI is the Center of Allelic Deletion on Chromosome lp31 in Ovarian and Breast Cancers," *Int J Cancer*, 86:690-4 (2000).
	--	Poggio T. et al., "Networks for Approximation and Learning," *Proceedings of IEEE* 78(9):1481-149 (1990).
	√	Precup D. et al., "Classification Using Φ-Machines and Constructive Function Approximation," *In Proc.* 15th International Conf. On Machine Learning, 439-444 (1998).
	√	Quinlan JR., "C4.5: Programs for Machine Learning," *Morgan-Kaufmann* (1993).
	√	Rumelhart, DE. et al., "Learning Internal Representations by Error Backpropagation," *Parallel Distributed Processing: Explorations in the Microstructures of Cognition*, MIT Press/Bradford Books (1986).
	√	Schmittgen TD. et al., "Quantitative Reverse Transcription-Polymerase Chain Reaction to Study mRNA Decay: Comparison of Endpoint and Real-Time Methods," *Anal Biochem*, 285:194-204 (2000).
	√	Schwartz PE. et al., "Circulating Tumor Markers in the Monitoring of Gynecologic Malignancies," *Cancer* 60:353-361 (1987).
	√	Sonoda K. et al., "A Novel Tumor-Associated Antigen Expressed in Human Uterine and Ovarian Carcinomas," *Cancer*, 77:1501-9 (1996).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/08 (2-92)
Sheet 1 of 2

Form PTO-1449	Docket Number (Optional) 0788.00063	Application Number 10/004,587
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Michael A. Tainsky, et al.	
(Use several sheets if necessary)	Filing Date 12-04-01	Group Art Unit

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS *(Including Author, Title, Date Pertinent Pages, Etc.)*

	√	Alizadeh, AA. et al., "Distinct Types of Diffuse Large B-cell Lymphoma Identified by Gene Expression Profiling," *Nature*, 403:503-511 (2000).
	√	An, A, et al., "A Learning System for More Accurate Classifications," *Lecture Notes in Artificial Intelligence*, 1418:426-441 (1998).
	√	Aunoble, B. et al., "Major Oncogenes and Tumor Suppressor Genes Involved in Epithelial Ovarian Cancer," *Int J Oncol* 16:567-76 (2000).
	√	Baron, A.T. et al., "Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer," *Cancer Epidemiology, Biomarkers & Prevention* 8:129-137 (1999).
	√	Bast, R.C. et al., "A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer," *N Engl J Med*, 309: 883-887 (1983).
	√	Bast, R.C. et al., "Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma," *J. Clin Invest*, 68:1331-1337 (1981).
	√	Bauer, R. et al., "Cloning and Characterization of the Drosophila Homologue of the AP-2 Transcription Factor," *Oncogene* 17:1911-1922 (1998).
	√	Berek, J.S. et al., "Serum Interleukin-6 Levels Correlate with Disease Status in Patients with Epithelial Ovarian Cancer," *Am J Obstet Gynecol* 164: 1038-1043 (1991).
	√	Bittner, M. et al., "Molecular Classification of Cutaneous Malignant Melanoma by Gene Expression Profiling," *Nature*, 406:536-540 (2000).
	√	Blake, C. et al., "UCI Machine Learning Respitory Content," (1998).
	√	Boyd, J. et al., "Hereditary Ovarian Cancer: Molecular Genetics and Clinical Implications," *Gynecol Oncol* 64:196-206 (1997).
	√	Breiman, L. et al., "Classification and Regression Trees," *Wadsworth and Brooks* (1984).
	--	Buettner, R. et al., "An alternatively spliced form of AP-2 encodes a negative regulator of transcriptional activation by AP-2," *Mol. Cell Biol*, 13:4174-4185 (1993).
	√	Chiao, P.J. et al., "Elevated Expression of the Ribosomal Protein S2 Gene in Human Tumors," *Molecular Carcinogenesis*, 5:219-231 (1992).
	√	Clark, P. et al., "The CN2 Induction Algorithm," *Machine Learning*, 3:261-283 (1989).
	√	Coleman, M.P., et al., "Trends in Cancer Incidence and Mortality," *IARC Scientific Publications*, 121:477-498 (1993).
	√	Deyo, J. et al., "drp, A Novel Protein Expressed at High Cell Density But Not During Growth Arrest," *DNA and Cell Biol* 17:437-447 (1998).
	√	Draghici, S., "The Constraint Based Decomposition," accepted for publication in *Neural Networks*, to appear (2001).
	√	Einhorn, N. et al., "Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer," *Obstet Gynecol*, 80:14-18 (1992).
	√	Golub, T.R. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring," *Science*, 286:531-537 (1999).